bioMerieux SA has acquired Hyglos GmbH to further develop its approaches in the detection of endotoxins within pharmaceutical products.
The sale consideration of the acquisition is $26.7m, which will be paid in phases over the next three years.
According to the agreement, Hyglos has been merged and consolidated into BioMerieux’s financial statements effective from 1 June 2016.
Recordati S.p.A plans to expand and strengthen its gastroenterology portfolio through its recent acquisition of 100% shares of Italchimici S.p.A.
The purchase consideration of the transaction is $145m, which has been funded from the existing facilities.
Share this article
